SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.400+1.7%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bobbseytwins2001 who wrote (1135)8/18/2025 10:48:52 AM
From: luckydog883 Recommendations

Recommended By
erippetoe
Fitzhughlaw
jargonweary

  Read Replies (1) of 1221
 
I am all for having a positive outlook on things in general, so I appreciate your point of view.

That being said, PSS has made owning IBRX stock a pretty depressing experience overall so far, as he has shown zero concern for shareholders outside of himself.

Like most of us here, we can only hope for an IMMU-like experience where things turn around at some point. Except in this case there can be no venbio/avoro coming to the rescue due to the ownership structure.

If institutions have zero to little interest in making money from investing in IBRX, it makes the road to higher stock prices a bit tougher.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News